Abstract Leigh syndrome is a mitochondrial disease characterized by neurological disorders, metabolic abnormalities, and premature death. There is no cure for Leigh syndrome; therefore, new therapeutic targets are urgently needed. In Ndufs4-KO mice, a mouse model of Leigh syndrome, we
Targeting NAD+ Metabolism as Interventions for Mitochondrial Disease
